Enviar artigo por via de e-mail Role of Drug – Drug Interactions in the Efficacy and Safety of Clarithromycin Treatment for Helicobacter Pylori Eradication
- Autores: Serebrova S.Y.1,2, Kareva E.N.2,3, Eremenko N.N.1,2, Prokof’ev A.B.1,2, Kurguzova D.O.2, Drozdov V.N.2, Lazareva N.B.2, Komissarenko I.A.4, Starodubtsev A.K.2
-
Afiliações:
- Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
- I. M. Sechenov First Moscow State Medical University (Sechenov University)
- N. I. Pirogov National Research Medical University
- A. I. Evdokimov Moscow State University of Medicine and Dentistry
- Edição: Volume 53, Nº 8 (2019)
- Páginas: 678-679
- Seção: Article
- URL: https://bakhtiniada.ru/0091-150X/article/view/245941
- DOI: https://doi.org/10.1007/s11094-019-02061-5
- ID: 245941
Citar
Acesso aberto
Acesso está concedido
Somente assinantes
Resumo
Current risks from resistance, adverse drug reactions, and drug – drug interactions of clarithromycin used as a component of Helicobacter pylori eradication therapy are reviewed. The acid sensitivity of clarithromycin i responsible for the dependence of its pharmacological properties on the efficacy of proton-pump inhibitors, which could be one reason for the resistance of H. pylori to the macrolide. The potential for clarithromycin drug – drug interactions is related to its metabolism by CYP3A4 and strong inhibition of this enzyme.
Sobre autores
S. Serebrova
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
Rússia, 8/2 Petrovskii Blvd., Moscow, 127051; 8/2 Trubetskaya St., Moscow, 119991
E. Kareva
I. M. Sechenov First Moscow State Medical University (Sechenov University); N. I. Pirogov National Research Medical University
Autor responsável pela correspondência
Email: kareva.en@1msmu.ru
Rússia, 8/2 Trubetskaya St., Moscow, 119991; 1 Ostrovityanova St., Moscow, 117997
N. Eremenko
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
Rússia, 8/2 Petrovskii Blvd., Moscow, 127051; 8/2 Trubetskaya St., Moscow, 119991
A. Prokof’ev
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
Rússia, 8/2 Petrovskii Blvd., Moscow, 127051; 8/2 Trubetskaya St., Moscow, 119991
D. Kurguzova
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
Rússia, 8/2 Trubetskaya St., Moscow, 119991
V. Drozdov
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
Rússia, 8/2 Trubetskaya St., Moscow, 119991
N. Lazareva
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
Rússia, 8/2 Trubetskaya St., Moscow, 119991
I. Komissarenko
A. I. Evdokimov Moscow State University of Medicine and Dentistry
Email: kareva.en@1msmu.ru
Rússia, 20/1 Delegatskaya St., Moscow, 127473
A. Starodubtsev
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
Rússia, 8/2 Trubetskaya St., Moscow, 119991
Arquivos suplementares
